Pfizer Inc. (PFE)
Nike Names Pfizer's Denton as Next CFO
David Denton's appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose
China outpacing Europe in drug innovation and development, Pfizer executive says
China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) reached $25.22 at the closing of the latest trading day, reflecting a -2.72% change compared to its last close.
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
Pfizer: Why I'm Still Expecting A Massive Rebound
Pfizer Inc. remains a Buy with 55%+ upside potential over two years, driven by a robust pipeline and undervalued forward earnings. PFE's Q1 2026 results beat estimates, with non-COVID sales up 7% YoY and strong contributions from Seagen and new product launches. Key catalysts include the potential blockbuster GLP-1 candidate berobenatide, aggressive oncology growth, and patent settlements extending revenue streams.
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.
